NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIDCR E-107-2022-1-ZA-01 Treatment Methods Of Triphenyl Calcilytic Compounds ZA National Stage 2023/04309 Pending
NIDCR E-107-2022-1-SG-01 TRIPHENYL CALCILYTIC COMPOUNDS FOR THE TREATMENT OF AUTOSOMAL DOMINANT HYPOCALCEMIA TYPE 1 (ADH1) SG National Stage 11202302007V Pending
NIDCR E-107-2022-1-CA-01 TRIPHENYL CALCILYTIC COMPOUNDS FOR THE TREATMENT OF AUTOSOMAL DOMINANT HYPOCALCEMIA TYPE 1 (ADH1) CA National Stage 3192684 Pending
NIDCR E-107-2022-1-MX-01 Treatment Methods Of Triphenyl Calcilytic Compounds MX National Stage MX/a/2023/003129 Pending
NIDCR E-107-2022-1-NZ-01 TRIPHENYL CALCILYTIC COMPOUNDS FOR THE TREATMENT OF AUTOSOMAL DOMINANT HYPOCALCEMIA TYPE 1 (ADH1) NZ National Stage 799089 Pending
NIDCR E-107-2022-1-IL-01 TRIPHENYL CALCILYTIC COMPOUNDS FOR THE TREATMENT OF AUTOSOMAL DOMINANT HYPOCALCEMIA TYPE 1 (ADH1) IL National Stage 301409 Pending
NCI E-237-2017-2-BR-18 T CELL RECEPTORS RECOGNIZING MUTATED P53 BR DIV BR122021018454-2 Pending
NCI E-181-2017-0-BR-22 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS BR DIV BR122021018418-6 Pending
NIDCR E-107-2022-1-AU-01 TRIPHENYL CALCILYTIC COMPOUNDS FOR THE TREATMENT OF AUTOSOMAL DOMINANT HYPOCALCEMIA TYPE 1 (ADH1) AU National Stage 2021343475 Pending
NIDCR E-107-2022-1-BR-01 TRIPHENYL CALCILYTIC COMPOUNDS FOR THE TREATMENT OF AUTOSOMAL DOMINANT HYPOCALCEMIA TYPE 1 (ADH1) BR National Stage BR112023005061-8 Pending
NCI E-210-2018-1-US-01 Chimeric Adaptor Proteins (CAPs) For Improved T-Cell Immunotherapy US CIP 17/475,810 Pending
NIAID E-166-2021-4-EP-01 Coronavirus Antibodies And Uses Thereof EP National Stage 21870173.8 Pending
NIAID E-166-2021-4-US-01 Coronavirus Antibodies And Uses Thereof US National Stage 18/026,544 Pending
NIAID E-166-2021-4-PCT-01 Coronavirus Antibodies And Uses Thereof PCT PCT COMB PCT/US2021/050552 Expired
NIAID E-166-2021-4-CA-01 Coronavirus Antibodies And Uses Thereof CA National Stage 3192706 Pending
NCI E-265-2015-0-CN-33 T CELL RECEPTORS RECOGNIZING HLA-CW8 RESTRICTED MUTATED KRAS CN DIV 202111083392.9 Pending
NIAID E-095-2019-0-US-04 HIV RNA VACCINES US National Stage 17/439,198 Pending
NCI E-171-2018-7-JP-11 MODIFIED CELLS AND METHODS OF THERAPY JP DIV 2021-149724 Pending
NHLBI E-025-2021-0-US-01 SYNTHETIC BRIGHT-BLOOD AND DARK-BLOOD PSIR LGE IMAGES US ORD 17/472,838 11454691 Issued PDF
NIDDK E-081-2019-0-US-02 Method For Improving Insulin Sensitivity US National Stage 17/438,580 Pending
NCI E-031-2020-0-CO-16 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION CO National Stage NC2022/0012922 Pending
NCI E-230-2012-0-KR-66 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 KR DIV 10-2021-7029207 Issued
NHLBI E-143-2021-1-PCT-03 TISSUE CUTTING SYSTEMS AND METHODS PCT PCT PCT/US2021/049952 Expired
NHLBI E-143-2021-1-IL-01 TISSUE CUTTING SYSTEMS AND METHODS IL National Stage 2073-10-30 Pending
NCI E-193-2020-0-PCT-02 RNASE H-ASSISTED DETECTION ASSAY FOR RNA PCT PCT PCT/US2021/049588 Expired
NCI E-042-2014-0-HK-30 Chimeric Antigen Receptors Targeting CD-19 HK EP 42021038427.7 Pending
NHLBI E-085-2019-0-US-05 METHODS FOR ASSESSING CARDIOVASCULAR DISEASE OR INFLAMMATORY DISEASE RISK USING NON-EXCHANGEABLE LIPID PROBE US National Stage 17/437,094 Pending
NCI E-167-2019-0-PCT-02 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY PCT PCT PCT/US2021/049387 Expired
NHLBI E-085-2019-0-EP-03 METHODS FOR ASSESSING CARDIOVASCULAR DISEASE OR INFLAMMATORY DISEASE RISK USING NON-EXCHANGEABLE LIPID PROBE EP National Stage 20769307.8 Pending
NCI E-094-2018-0-HK-09 METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF HK EP 62021038049.4 Pending
NCI E-173-2020-0-PCT-02 T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATIONS IN P53 PCT PCT PCT/US2021/048786 Expired
NCI E-173-2020-0-TW-03 T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATION IN P53 TW ORD 110132552 Pending
NCI E-174-2012-0-US-04 METHODS OF PRODUCING T MEMORY STEM CELL POPULATIONS US CON 17/465,577 Pending
NCI E-265-2015-0-NZ-34 T CELL RECEPTORS RECOGNIZING HLA-CW8 RESTRICTED MUTATED KRAS NZ DIV 779633 Pending
NCI E-163-2020-0-PCT-02 LZK-TARGETING DEGRADERS AND METHODS OF USE PCT PCT PCT/US2021/048600 Expired
NCI E-163-2020-0-HK-01 LZK-TARGETING DEGRADERS AND METHODS OF USE HK National Stage 62023082317.6 Pending
NHLBI E-085-2019-0-IL-04 METHODS FOR ASSESSING CARDIOVASCULAR DISEASE OR INFLAMMATORY DISEASE RISK USING NON-EXCHANGEABLE LIPID PROBE IL National Stage 286023 Pending
NCI E-230-2012-0-CN-65 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 CN DIV 202111028896.0 Pending
NHLBI E-126-2020-0-PCT-02 Methods To Produce Very Long Chain Fatty Acids (VLCFA) PCT PCT PCT/US2021/048390 Expired
NIDCD E-004-2019-1-US-07 ADENO-ASSOCIATED VIRUSES AND THEIR USES FOR INNER EAR THERAPY US National Stage 17/435,365 Pending
NIAID E-081-2013-4-MX-18 Prefusion RSV F Proteins And Their Use MX DIV MX/a/2021/010519 Pending
NCI E-040-2012-0-IN-64 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen IN DIV 202148039207 Pending
NCATS E-014-2022-0-PCT-02 HYDROXYNORKETAMINE COMPOUNDS AND METHODS OF USE THEREOF PCT PCT PCT/US2021/048095 Expired
NCI E-055-2017-0-EP-08 Combination Therapy of Immunotoxin and Checkpoint Inhibitor EP DIV 21193555.6 Pending
NCI E-213-2018-0-HK-09 TRITERPENE AMINE DERIVATIVES HK EP 62021037592.4 Pending
NCI E-098-2018-0-HK-07 T CELL RECEPTORS WHICH RECOGNIZE MUTATED EGFR HK EP 62021037536.1 Pending
NCI E-148-2011-0-US-52 ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III CHIMERIC ANTIGEN RECEPTORS AND USE OF SAME FOR THE TREATMENT OF CANCER US CON 17/410,129 11879017 Issued PDF
NIAID E-057-2011-2-US-06 VIRUS-LIKE PARTICLES AND METHODS OF USE US CON 17/410,182 11718647 Issued PDF
NCI E-109-2020-0-PCT-02 PREFERENTIAL GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES PCT PCT PCT/US2021/046969 Expired
NIAID E-297-2016-2-AU-08 VACCINE CANDIDATES FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) HAVING ATTENUATED PHENOTYPES AU DIV 2021218112 Issued